证券研究报告 | 公司点评 | 医疗服务 凯莱英(002821) 报告日期：2025 年 04 月 24 日 新兴业务发力，看好持续性 ——凯莱英 2025Q1 业绩点评 投资要点 2025Q1 公司实现营业收入 15.41 亿元（YOY10.10%）,归母净利润 3.27 亿 （YOY15.83%），扣非净利润 3.05 亿（YOY20.14%）。 从业务拆分看：小分子业务保持稳定发展，收入基本持平。新兴业务收入同比增 长超 80%，公司持续加大市场开拓力度和业务竞争力提升，特别是多肽、寡核苷 酸、ADC 等增量业务，我们仍然看好新兴业务持续发力。 ❑ 盈利能力：新兴业务毛利率显著提升，看好持续性 25Q1 实现毛利率 42.54%（同比-0.98pct），其中小分子业务毛利率 45.17%（同比 -2.17pct），新兴业务毛利率 33.05%（同比+15.75pct，我们认为主要来自于新兴 业务订单持续交付下产能利用率持续提升带来的规模化效应），明显回升。 净利率看 25Q1 净利率 21.06%（同比+1.09pct），其中研发费用率同比-3.15pct， 管理费用率同比-0.41pct，销售费用率同 ...

截至4月24日收盘，CRO概念上涨0.96%，位居概念板块涨幅第9，板块内，38股上涨，金凯生科20%涨 停，双成药业、河化股份、凯莱英等涨停，峆一药业、博腾股份、昊帆生物等涨幅居前，分别上涨 6.50%、5.35%、4.50%。跌幅居前的有星昊医药、康鹏科技、蔚蓝生物等，分别下跌8.43%、4.30%、 3.46%。 今日涨跌幅居前的概念板块 | 业 | | --- | | 603259 | 药明康 | 0.36 | 1.49 | 2800.31 | 1.32 | | --- | --- | --- | --- | --- | --- | | | 德 | | | | | | 300363 | 博腾股 | 5.35 | 5.1 1 | 2230.39 | 5.99 | | | 份 | | | | | | 300725 | 药石科 | 0.38 | 4.14 | 1420.31 | 6.43 | | | 技 | | | | | | 300347 | 泰格医 | 0.35 | 1.99 | 1315.18 | 2.54 | | | 药 | | | | | | | 圣诺生 | | | | | | 688117 | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company achieved a revenue of 1.541 billion yuan in Q1 2025, representing a year-over-year growth of 10.10%, and a net profit attributable to shareholders of 327 million yuan, with a year-over-year increase of 15.83%. The non-recurring net profit was 305 million yuan, reflecting a year-over-year growth of 20.14% [1] - The emerging business segment saw revenue growth exceeding 80% year-over-year, driven by increased market expansion efforts and enhanced competitiveness, particularly in peptide, oligonucleotide, and ADC businesses. The outlook for the emerging business remains positive [1][2] - The gross margin for Q1 2025 was 42.54%, with the emerging business gross margin significantly improving to 33.05%, a year-over-year increase of 15.75%. This improvement is attributed to higher capacity utilization from sustained order deliveries [2] - The company forecasts EPS for 2025-2027 to be 2.90, 3.45, and 4.19 yuan, respectively, with a PE ratio of 23 times based on the closing price on April 23, 2025. The company is expected to maintain strong growth potential, particularly in the emerging business segment [2] Financial Summary - For 2025E, the company expects revenue of 6.629 billion yuan, a year-over-year increase of 14.21%, and a net profit of 1.045 billion yuan, reflecting a growth of 10.16% [7] - The gross margin is projected to be 42.43% in 2025E, with a net margin of 15.72% [8] - The company’s total assets are expected to reach 21.751 billion yuan by 2025E, with total liabilities of 2.771 billion yuan [8]

沪指4月24日上涨0.03%，申万所属行业中，今日上涨的有10个，涨幅居前的行业为美容护理、银行， 涨幅分别为1.61%、1.16%。医药生物行业今日上涨0.25%。跌幅居前的行业为计算机、通信，跌幅分别 为2.36%、2.08%。 主力资金净流出的行业有25个，电子行业主力资金净流出规模居首，全天净流出资金66.21亿元，其次 是计算机行业，净流出资金为64.60亿元，净流出资金较多的还有机械设备、通信、汽车等行业。 医药生物行业今日上涨0.25%，全天主力资金净流入2.65亿元，该行业所属的个股共476只，今日上涨的 有243只，涨停的有10只；下跌的有218只，跌停的有3只。以资金流向数据进行统计，该行业资金净流 入的个股有204只，其中，净流入资金超5000万元的有10只，净流入资金居首的是双成药业，今日净流 入资金1.81亿元，紧随其后的是凯莱英、金凯生科，净流入资金分别为1.63亿元、1.37亿元。医药生物 行业资金净流出个股中，资金净流出超3000万元的有9只，净流出资金居前的有花园生物、迈瑞医疗、 智飞生物，净流出资金分别为8240.77万元、6250.66万元、6132.45万元。（数据宝） ...

Investment Rating - The report maintains a "Strong Buy" rating for the company, indicating an expected stock performance that will exceed the market by more than 20% within the next six months [14]. Core Insights - The company achieved a revenue of 1.541 billion yuan in Q1 2025, reflecting a year-on-year growth of 10.10%. The net profit attributable to shareholders was 327 million yuan, up 15.83% year-on-year, with a non-recurring net profit of 305 million yuan, increasing by 20.14% [5][6]. - The overall gross margin for Q1 2025 was 42.54%, showing a slight decrease of 0.98 percentage points. However, the net profit margin improved to 21.19%, an increase of 1.05 percentage points, indicating better profit growth compared to revenue growth [6]. - The emerging business segment saw a revenue increase of over 80% year-on-year, contributing significantly to the overall revenue growth, particularly from peptide, small nucleic acid, and ADC businesses [7]. Summary by Sections Financial Performance - Q1 2025 revenue was 1.541 billion yuan, with a gross margin of 42.54% and a net profit margin of 21.19% [5][6]. - The company forecasts net profits of 1.126 billion yuan, 1.378 billion yuan, and 1.740 billion yuan for 2025, 2026, and 2027 respectively [7]. Business Segments - Small molecule revenue remained stable compared to the previous year, with a gross margin of 45.17%. The emerging business segment's revenue exceeded 317 million yuan, continuing its strong performance from Q4 2024 [7]. - The report highlights the potential for growth in small molecule business revenue and margins throughout the year due to ongoing projects and production cycles [7]. Future Projections - The company is expected to see a recovery in global innovative drug development, which will positively impact its business performance [7]. - The report maintains profit forecasts for 2025-2027, projecting a gradual increase in revenue and net profit margins over the years [8][12].

证券研究报告 | 公司点评报告 2025 年 04 月 24 日 凯莱英（002821.SZ） 财务数据与估值 | 会计年度 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 7825 | 5805 | 6617 | 7627 | 8859 | | 同比增长 | -24% | -26% | 14% | 15% | 16% | | 营业利润(百万元) | 2571 | 1079 | 1237 | 1455 | 1810 | | 同比增长 | -31% | -58% | 15% | 18% | 24% | | 归母净利润(百万元) | 2269 | 949 | 1078 | 1265 | 1569 | | 同比增长 | -31% | -58% | 14% | 17% | 24% | | 每股收益(元) | 6.29 | 2.63 | 2.99 | 3.51 | 4.35 | | PE | 10.7 | 25.5 | 22.4 | 19.1 | 15.4 | | PB | 1.4 ...

行业一季度复苏明显，CRO概念股今日表现活跃。 截至午间收盘，金凯生科20CM涨停，河化股份、凯莱英、灵康药业（维权）涨停，双成药业涨超7%，昊帆生物涨超3%，翰宇药业涨超2%。 | 名称 | 现价 | 强调 | 年初至今 | | --- | --- | --- | --- | | 金凯生科 | 31.48 | +20.02 | +21.64% | | 河化股份 | 6.26 | +10.02 | +11.99% | | 凯莱英 | 73.77 | +10.01 | -3.05% | | 灵康药业 | 4.62 | +10.00 | -12.00% | | 双成药业 | 10.27 | +7.31 | -43.97% | | 新大地 | 13.35 | +4.38 | +39.16% | | 吴帆生物 | 47.30 | +3.84 | +18.52% | | 博腾股份 | 14.56 | +3.78 | -7.67% | | 哈一药业 | 29.10 | +3.30 | +73.52% | | 翰宇药业 | 14.64 | +2.23 | +13.58% | | 诺泰生物 | 54.20 | +1.98 | ...

[Table_Title2] 凯莱英(002821) [Table_Summary] 事件概述 [Table_Date] 2025 年 04 月 24 日 [Table_Title] 业绩符合市场预期，新兴业务收入同比增长超 80% 公司发布 2025 年一季报：25Q1 实现营业收入 15.41 亿元，同比 增长 10.10%、实现归母净利润 3.27 亿元，同比增长 15.83%、 实现扣非净利润 3.05 亿元，同比增长 20.14%。 分析判断: 证券研究报告|公司点评报告 邮箱：cuiwl@hx168.com.cn SAC NO：S1120519110002 联系电话： ► 业绩符合市场预期，新兴业务收入同比增长超 80% 公司 25Q1 实现收入 15.41 亿元，同比增长 10.10%、实现归母净 利润 3.27 亿元，同比增长 15.83%，符合之前市场预期。受益于 多肽、寡核苷酸、ADC 等业务的放量，公司 25Q1 新兴业务实现收 入超过 3.1 亿元（24Q1 披露新兴业务收入 1.76 亿元，同比增长 超过 80%，即为收入端超过 3.1 亿元），同比增长超过 80%，对应 毛利率提升 ...

新股方面，今天A股市场有两只新股上市，悉数大幅上涨，其中新股江顺科技（001400）盘中涨幅一度超过120%。 港股市场盘中走低，不过仍有不少股票大涨，其中凯莱英（002821）港股盘中一度大涨超19%。 CXO、维生素、电力等板块逆市走强。 今天上午A股市场整体窄幅震荡，电力、CXO、维生素等概念板块走强。 A股市场窄幅震荡 今天上午A股市场整体窄幅震荡走低。截至午间收盘，上证指数跌0.1%，深证成指跌0.66%，北证50指数跌2.8%，创业 板指跌0.68%。 主要行业板块和赛道方面，日用化工、煤炭、造纸、农林牧渔等板块涨幅居前。软件服务、互联网、矿物制品、IT设 备等板块跌幅居前。 | 电力板块走强，华银电力（600744）、西昌电力（600505）、郴电国际（600969）等多股涨停，另有多股大幅上涨。 | | --- | | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 ▼ | | --- | --- | --- | --- | --- | | 600744 | 华银电力 | 3.85 | 0.35 | 10.00% | | 600505 | 西昌电力 | 17.31 | 1.57 | 9.97% ...

Core Viewpoint - The A-share market experienced a narrow fluctuation today, with certain sectors such as electricity, CXO, and vitamins showing strength despite the overall market trend [2][6]. Group 1: Market Performance - The A-share market showed a slight decline, with the Shanghai Composite Index down 0.1%, the Shenzhen Component down 0.66%, the North Star 50 Index down 2.8%, and the ChiNext Index down 0.68% [6]. - The electricity sector performed well, with stocks like Huayin Power, Xichang Power, and Chenzhou International reaching their daily limit up [7][8]. - New stocks listed today saw significant gains, with Jiangshun Technology's intraday increase exceeding 120% [3][15]. Group 2: Sector Highlights - The electricity sector saw notable gains, with multiple stocks experiencing significant increases, including Huayin Power at 10% up, Xichang Power at 9.97% up, and Chenzhou International at 9.95% up [8]. - The CXO sector also showed strong performance, with Jin Kai Sheng Ke hitting the daily limit up and other stocks like Hehua Co., Kailai Ying A-shares, and Lingkang Pharmaceutical also reaching their limits [10]. - The vitamin sector demonstrated a clear upward trend, contributing to the overall strength of the market [8]. Group 3: New Stock Listings - Two new stocks were listed today, both experiencing substantial increases, with Jiangshun Technology's stock price rising significantly [14][15]. - Tian You Wei, another new stock, saw its price increase by nearly 50% during the trading session [16]. Group 4: Hong Kong Market - The Hong Kong market experienced a decline, with the Hang Seng Index dropping over 1% [17][19]. - Despite the overall downturn, stocks like New Oriental saw significant gains, with an intraday increase exceeding 6% following the release of their financial results [20].